These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34374173)

  • 21. An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis.
    Ošep AB; Brecl E; Škerget M; Savšek L
    Clin Neurol Neurosurg; 2023 May; 228():107675. PubMed ID: 36965418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
    Kim H; Lee EJ; Kim SK; Kim KK; Lim YM
    Mult Scler Relat Disord; 2019 May; 30():247-251. PubMed ID: 30849681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case Report: Delayed Alemtuzumab-Induced Concurrent Neutropenia and Thrombocytopenia in Relapsing-Remitting Multiple Sclerosis.
    Ganju A; Stock JC; Jordan K
    J Pharm Pract; 2023 Feb; 36(1):168-172. PubMed ID: 34169768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    Frau J; Coghe G; Lorefice L; Fenu G; Musu L; Cocco E
    J Neurol; 2019 Jun; 266(6):1405-1411. PubMed ID: 30863891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure changes during alemtuzumab infusion for multiple sclerosis patients.
    Shosha E; Casserly C; Tomkinson C; Morrow SA
    Eur J Neurol; 2021 Apr; 28(4):1396-1400. PubMed ID: 33175474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
    Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
    J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.
    Knudsen MH; Lindberg U; Frederiksen JL; Vestergaard MB; Simonsen HJ; Varatharaj A; Galea I; Blinkenberg M; Sellebjerg F; Larsson HBW; Cramer SP
    Mult Scler Relat Disord; 2022 Jul; 63():103891. PubMed ID: 35661562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
    Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
    Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Vavasour IM; Tam R; Li DK; Laule C; Taylor C; Kolind SH; MacKay AL; Javed A; Traboulsee A
    Mult Scler; 2019 May; 25(6):811-818. PubMed ID: 29663845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.
    Myro AZ; Bjerke G; Zarnovicky S; Holmøy T
    BMC Pharmacol Toxicol; 2018 Nov; 19(1):75. PubMed ID: 30454022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.
    Syed YY
    Drugs; 2021 Jan; 81(1):157-168. PubMed ID: 33367970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
    Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
    CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.